These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 15107001)
1. A free energy based computational pathway from chemical templates to lead compounds: a case study of COX-2 inhibitors. Latha N; Jain T; Sharma P; Jayaram B J Biomol Struct Dyn; 2004 Jun; 21(6):791-804. PubMed ID: 15107001 [TBL] [Abstract][Full Text] [Related]
2. Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site? Soliva R; Almansa C; Kalko SG; Luque FJ; Orozco M J Med Chem; 2003 Apr; 46(8):1372-82. PubMed ID: 12672237 [TBL] [Abstract][Full Text] [Related]
3. Recognition of cyclooxygenase-2 (COX-2) active site by NSAIDs: a computer modelling study. Kothekar V; Sahi S; Srinivasan M; Mohan A; Mishra J Indian J Biochem Biophys; 2001; 38(1-2):56-63. PubMed ID: 11563332 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. Praveen Rao PN; Amini M; Li H; Habeeb AG; Knaus EE J Med Chem; 2003 Nov; 46(23):4872-82. PubMed ID: 14584938 [TBL] [Abstract][Full Text] [Related]
5. Cox-2-selective inhibitors: the new super aspirins. DeWitt DL Mol Pharmacol; 1999 Apr; 55(4):625-31. PubMed ID: 10101019 [No Abstract] [Full Text] [Related]
7. Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints. Hsu N; Cai D; Damodaran K; Gomez RF; Keck JG; Laborde E; Lum RT; Macke TJ; Martin G; Schow SR; Simon RJ; Villar HO; Wick MM; Beroza P J Med Chem; 2004 Sep; 47(20):4875-80. PubMed ID: 15369391 [TBL] [Abstract][Full Text] [Related]
8. A CoMFA study of COX-2 inhibitors with receptor based alignment. Datar PA; Coutinho EC J Mol Graph Model; 2004 Dec; 23(3):239-51. PubMed ID: 15530820 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Selvam C; Jachak SM; Thilagavathi R; Chakraborti AK Bioorg Med Chem Lett; 2005 Apr; 15(7):1793-7. PubMed ID: 15780608 [TBL] [Abstract][Full Text] [Related]
10. Computer simulation of the interaction of non-steroidal anti-inflammatory drugs: indoprofen and NS398 with cyclooxygenase. Kothekar V; Sahi S; Srinivasan M J Biomol Struct Dyn; 1999 Feb; 16(4):901-15. PubMed ID: 10217458 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of indomethacin analogues that inhibit P-glycoprotein and/or multidrug resistant protein without COX inhibitory activity. Arisawa M; Kasaya Y; Obata T; Sasaki T; Nakamura T; Araki T; Yamamoto K; Sasaki A; Yamano A; Ito M; Abe H; Ito Y; Shuto S J Med Chem; 2012 Sep; 55(18):8152-63. PubMed ID: 22916727 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of N-acetyl-2-(or 3-)carboxymethylbenzenesulfonamides as cyclooxygenase isozyme inhibitors. Chen QH; Rao PN; Knaus EE Bioorg Med Chem; 2005 Aug; 13(15):4694-703. PubMed ID: 15914011 [TBL] [Abstract][Full Text] [Related]
13. Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin. Tosco P; Lazzarato L ChemMedChem; 2009 Jun; 4(6):939-45. PubMed ID: 19301318 [TBL] [Abstract][Full Text] [Related]
14. 1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors. Biava M; Porretta GC; Cappelli A; Vomero S; Manetti F; Botta M; Sautebin L; Rossi A; Makovec F; Anzini M J Med Chem; 2005 May; 48(9):3428-32. PubMed ID: 15857149 [TBL] [Abstract][Full Text] [Related]
15. Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. Kalgutkar AS; Kozak KR; Crews BC; Hochgesang GP; Marnett LJ J Med Chem; 1998 Nov; 41(24):4800-18. PubMed ID: 9822550 [TBL] [Abstract][Full Text] [Related]
16. Enzyme selectivity of new cyclooxygenase-2/5 lipoxygenase inhibitors using molecular modeling approach. Kothekar V; Sahi S; Mishra J Indian J Biochem Biophys; 2000 Apr; 37(2):86-96. PubMed ID: 10983419 [TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of subtype-selective cyclooxygenase (COX) inhibitors derived from thalidomide. Sano H; Noguchi T; Tanatani A; Hashimoto Y; Miyachi H Bioorg Med Chem; 2005 May; 13(9):3079-91. PubMed ID: 15809144 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series. Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960 [TBL] [Abstract][Full Text] [Related]
19. [Studied on docking of 5,6-diaryl-2,3-dihydro-1-pyrrolizinone derivatives with cyclooxygenase]. Zhao LQ; Hu YD; Yuan Y; Zhang T; Zhang SF; Li S Yao Xue Xue Bao; 2001 Jun; 36(6):415-8. PubMed ID: 12585123 [TBL] [Abstract][Full Text] [Related]
20. Research strategies for design and development of NSAIDs: clue to balance potency and toxicity of acetanilide compounds. Pal AK; Sen S; Ghosh S; Bera AK; Bhattacharya S; Chakraborty S; Banerjee A J Biomol Struct Dyn; 2001 Aug; 19(1):85-93. PubMed ID: 11565854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]